Olipass (XKRX:244460) Debt-to-Asset : 0.54 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Olipass Debt-to-Asset?

Olipass's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩3,278 Mil. Olipass's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩4,427 Mil. Olipass's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was ₩14,357 Mil. Olipass's debt to asset for the quarter that ended in Sep. 2024 was 0.54.

Olipass Debt-to-Asset Historical Data

The historical data trend for Olipass's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olipass Debt-to-Asset Chart

Olipass Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.53

0.31

0.25

0.28

0.26

Olipass Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.40	0.26	0.51	0.45	0.54

Competitive Comparison of Olipass's Debt-to-Asset

For the Biotechnology subindustry, Olipass's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Olipass's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olipass's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Olipass's Debt-to-Asset falls into.

Olipass Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Olipass's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3383.196	+	205.198)	/	13609.598
	=	0.26

Olipass's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3278.013	+	4427.358)	/	14356.96
	=	0.54

Olipass (XKRX:244460) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Olipass Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Olipass's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Olipass Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olipass Corp (XKRX:244460) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

16-4, 16 Beon-gil, Dongbaek Jungang-ro, Ace Dongbaek Tower 20th Floor, Giheung-gu, Yongin, KOR, 17015

Website

https://www.olipass.com

Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.

Olipass Headlines

No Headlines